Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remission.
暂无分享,去创建一个
J. Sierra | A. Zander | M. Horowitz | M. Tallman | R. Gale | M. Bishop | J. Liesveld | P. McCarthy | A. Keating | G. Schiller | H. Lazarus | J. Rowe | D. Weisdorf | R. Maziarz | M. Laughlin | M. Litzow | S. Luger | R. Weiner | A. Bashey | D. Marks | O. Ilhan | J. Cahn | S. Frankel | Mei-Jie Zhang | G. Milone | J. Russell | J. Garcia | R. Saez | G. Phillips | N. Christiansen | S. Pavlovsky | C. Linker | W. Pérez | J. Garcia
[1] C. Sawyers,et al. Transplantation of IL-2-mobilized autologous peripheral blood progenitor cells for adults with acute myelogenous leukemia in first remission , 2001, Leukemia.
[2] M. Guiguet,et al. Improved efficiency of remission induction facilitates autologous BMT harvesting and improves overall survival in adults with AML: 108 patients treated at a single institution , 2001, Bone Marrow Transplantation.
[3] M. Horowitz,et al. Effect of postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission. , 2000, Blood.
[4] J. Sierra,et al. No impact of high‐dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission , 2000, British journal of haematology.
[5] E. Ball,et al. Autologous bone marrow transplantation for acute myeloid leukemia in remission or first relapse using monoclonal antibody-purged marrow: results of phase II studies with long-term follow-up , 2000, Bone Marrow Transplantation.
[6] C. Bloomfield,et al. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] F. Gherlinzoni,et al. Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells , 1999, Bone Marrow Transplantation.
[8] J P Klein,et al. Testing for centre effects in multi-centre survival studies: a Monte Carlo comparison of fixed and random effects tests. , 1999, Statistics in medicine.
[9] J Crowley,et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.
[10] C. Bloomfield,et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. , 1998, Cancer research.
[11] Keith Wheatley,et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial , 1998, The Lancet.
[12] K. Akashi,et al. Autologous peripheral blood stem cell transplantation for acute myelogenous leukemia , 1997, Bone Marrow Transplantation.
[13] C. Sawyers,et al. Transplantation of autologous peripheral blood progenitor cells procured after high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia in first remission , 1997, Leukemia.
[14] J. Klein,et al. Survival Analysis: Techniques for Censored and Truncated Data , 1997 .
[15] S. Singhal,et al. Autologous bone marrow transplantation for acute myeloid leukemia in first remission: identification of modifiable prognostic factors. , 1995, Bone marrow transplantation.
[16] J. Klein,et al. Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in first remission. , 1995, Bone marrow transplantation.
[17] R. Gingrich,et al. Improved outcome for high-risk acute myeloid leukemia patients using autologous bone marrow transplantation and monoclonal antibody-purged bone marrow. , 1994, Blood.
[18] A. Grañena,et al. Autologous bone marrow transplantation for acute leukemia: results and prognostic factors in 90 consecutive patients. , 1993, Bone marrow transplantation.
[19] J. Thompson,et al. Interleukin-2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia. , 1993, Bone marrow transplantation.
[20] M. Oken,et al. Autologous bone marrow transplant in acute myeloid leukemia in first remission. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] R. Motzer,et al. Autologous bone marrow transplantation for acute myelogenous leukemia using 4-hydroperoxycyclophosphamide and VP-16 purged bone marrow. , 1992, Bone marrow transplantation.
[22] T. Kataoka,et al. [Autologous bone marrow transplantation for acute leukemia]. , 1991, [Rinsho ketsueki] The Japanese journal of clinical hematology.
[23] M. Labopin,et al. Autologous blood cell vs marrow transplantation for acute myeloid leukemia in complete remission: an EBMT retrospective analysis , 2000, Bone Marrow Transplantation.
[24] A. Grañena,et al. Treatment with interleukin-2 (IL-2) and interferon (IFNalpha 2b) after autologous bone marrow or peripheral blood stem cell transplantation in onco-hematological malignancies with a high risk of relapse , 1999, Bone Marrow Transplantation.